CN105943658A - Medicine for treating polycystic ovarian syndrome, as well as preparation method and application thereof - Google Patents
Medicine for treating polycystic ovarian syndrome, as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN105943658A CN105943658A CN201610476727.6A CN201610476727A CN105943658A CN 105943658 A CN105943658 A CN 105943658A CN 201610476727 A CN201610476727 A CN 201610476727A CN 105943658 A CN105943658 A CN 105943658A
- Authority
- CN
- China
- Prior art keywords
- medicine
- weight portion
- water
- solution
- hour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 149
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 78
- 206010036049 Polycystic ovaries Diseases 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 title abstract description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 241000914162 Rosa bella Species 0.000 claims abstract description 25
- 235000016607 Rosa bella Nutrition 0.000 claims abstract description 25
- 239000000706 filtrate Substances 0.000 claims abstract description 16
- 238000001514 detection method Methods 0.000 claims abstract description 15
- 239000006187 pill Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 239000007902 hard capsule Substances 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 9
- 238000002791 soaking Methods 0.000 claims abstract description 9
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical group O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000008187 granular material Substances 0.000 claims abstract description 3
- 239000007901 soft capsule Substances 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 72
- 238000011282 treatment Methods 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 33
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 29
- 238000012360 testing method Methods 0.000 claims description 29
- 239000013558 reference substance Substances 0.000 claims description 25
- 229930182603 Euscaphic acid Natural products 0.000 claims description 23
- OXVUXGFZHDKYLS-QUFHAEKXSA-N euscaphic acid Chemical compound C1[C@@H](O)[C@@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C OXVUXGFZHDKYLS-QUFHAEKXSA-N 0.000 claims description 23
- DQGMPXYVZZCNDQ-KDQYYBQISA-N 8Z,10E,12Z-octadecatrienoic acid Chemical compound CCCCC\C=C/C=C/C=C\CCCCCCC(O)=O DQGMPXYVZZCNDQ-KDQYYBQISA-N 0.000 claims description 22
- DQGMPXYVZZCNDQ-XUAYTHHASA-N Jacaric acid Natural products CCCCCC=C/C=C/C=CCCCCCCC(=O)O DQGMPXYVZZCNDQ-XUAYTHHASA-N 0.000 claims description 22
- 208000025661 ovarian cyst Diseases 0.000 claims description 11
- -1 filters Substances 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 8
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 6
- 238000013461 design Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 240000000971 garden vetch Species 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims 2
- 241000109294 Rosa suffulta Species 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 5
- 238000001035 drying Methods 0.000 abstract description 4
- 239000003826 tablet Substances 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241001407301 Berberis amurensis Species 0.000 abstract 2
- 238000011049 filling Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000000227 grinding Methods 0.000 abstract 1
- 229940100688 oral solution Drugs 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 58
- 210000004369 blood Anatomy 0.000 description 54
- 210000003734 kidney Anatomy 0.000 description 40
- 239000000243 solution Substances 0.000 description 35
- 206010062717 Increased upper airway secretion Diseases 0.000 description 33
- 208000026435 phlegm Diseases 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 230000007812 deficiency Effects 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 17
- 210000001672 ovary Anatomy 0.000 description 16
- 238000011160 research Methods 0.000 description 16
- 208000021267 infertility disease Diseases 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 230000027758 ovulation cycle Effects 0.000 description 12
- 230000035935 pregnancy Effects 0.000 description 12
- 230000016087 ovulation Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 201000000736 Amenorrhea Diseases 0.000 description 10
- 206010001928 Amenorrhoea Diseases 0.000 description 10
- 231100000540 amenorrhea Toxicity 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000008506 pathogenesis Effects 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 238000004080 punching Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 229960005309 estradiol Drugs 0.000 description 8
- 229930182833 estradiol Natural products 0.000 description 8
- 230000005906 menstruation Effects 0.000 description 8
- 239000003098 androgen Substances 0.000 description 7
- 239000000186 progesterone Substances 0.000 description 7
- 229960003387 progesterone Drugs 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 210000004291 uterus Anatomy 0.000 description 7
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000003054 hormonal effect Effects 0.000 description 6
- 201000010066 hyperandrogenism Diseases 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 208000019255 Menstrual disease Diseases 0.000 description 5
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 5
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003172 expectorant agent Substances 0.000 description 5
- 230000003419 expectorant effect Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 5
- 239000008164 mustard oil Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 206010020112 Hirsutism Diseases 0.000 description 4
- 208000037093 Menstruation Disturbances Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 230000003821 menstrual periods Effects 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 231100001274 therapeutic index Toxicity 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
- 206010011732 Cyst Diseases 0.000 description 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001071795 Gentiana Species 0.000 description 3
- 206010021033 Hypomenorrhoea Diseases 0.000 description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 229960003399 estrone Drugs 0.000 description 3
- 239000000745 gonadal hormone Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000002175 menstrual effect Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 210000003684 theca cell Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 201000005670 Anovulation Diseases 0.000 description 2
- 206010002659 Anovulatory cycle Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 231100000552 anovulation Toxicity 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 2
- 229960003608 clomifene Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000001113 umbilicus Anatomy 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000616862 Belliella Species 0.000 description 1
- 240000000724 Berberis vulgaris Species 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- 241001232809 Chorista Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- QYZBCWXZSYTIOY-UHFFFAOYSA-N Mercuric oxide Chemical compound [O-2].[Hg+2] QYZBCWXZSYTIOY-UHFFFAOYSA-N 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 244000248825 Peltandra virginica Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 201000010272 acanthosis nigricans Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229960005471 androstenedione Drugs 0.000 description 1
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000009362 danggui-shaoyao-san Substances 0.000 description 1
- 239000009752 danzhi xiaoyao Substances 0.000 description 1
- 239000009709 daotan Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008144 egg development Effects 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000005525 fibrillarin Human genes 0.000 description 1
- 108020002231 fibrillarin Proteins 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000008956 guizhi-fuling Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008629 longdanxiegan Substances 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000010417 needlework Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000006259 progesterone secretion Effects 0.000 description 1
- 210000004061 pubic symphysis Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000009705 sanhuang Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000008346 uterine blood flow Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000008539 xiaoyao Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the field of traditional Chinese medicines, and particularly relates to a medicine for treating polycystic ovarian syndrome, as well as a preparation method and application thereof. The medicine is prepared from the following raw materials in parts by weight: 1-2 parts of rosa bella rehd and 1-2 parts of berberis amurensis. The medicine can be prepared into tablets, pills, powder, hard capsules, soft capsules, granules and oral solution. The preparation method comprises the following steps: soaking dried rosa bella rehd and berberis amurensis in water which is 11 times amount of the medicinal materials for 1 hour for the first time, and decocting for 1 hour; adding 4 times amount of water for the second time, and decocting for 1 hour; and mixing decoctions, filtering, concentrating filtrate, drying, grinding into fine powder, screening, uniformly mixing and filling hard capsules. According to the chromatographic condition of the drug quality detection method, HypersilDs chromatographic column is adopted, the mobile phase is acetonitrile-water in a proportion of 30:70, the detection wavelength is 200nm, the column temperature is 20 DEG C, the flow velocity is 1.0mL.min<-1>, and the sample size is 10mu L.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of Rosa bella Rehd et wils and the active medicine of yellow calamite and preparation side thereof
Method.
Background technology
Polycystic ovarian syndrome (PCOS) is the Female Genital Endocrine systemic disease of a kind of many causes, polymorphism, is blue or green
Phase in spring and Female in child bearing period clinic is multiple, common, one of difficult disease.PCOS sickness rate in Female in child bearing period is up to 6% ~
10%.There are some researches show, have 75% fertility, the amenorrhea of 26% ~ 37%, 87% ~ 90% hypomenorrhea all may be with
PCOS is relevant.For the treatment of PCOS, how improving ovulation rate, pregnancy rate and gestation is problem in the urgent need to address, is also
In place of the difficult point for the treatment of primary disease, in recent years, Chinese medicine PCOS, from entirety, uses differential diagnosis of diseases and the dialectical method combined
Carry out diagnosis and treatment, achieve the goodst clinical effectiveness.
1 etiology and pathogenesis research
PCOS is clinical, and with androgen, too much and chronic anovulation is as principal character, show as hypomenorrhea even amenorrhea, infertile,
Hirsutism, obesity, acne, acanthosis nigricans etc., be to cause that Women of Childbearing Age is infertile, the modal cause of disease of menoxenia, be because of internal organs
The series of complex syndrome that the pathological products such as functional disorder, qi-blood disharmony, the turbid damp expectorant stasis of blood are jammed uterus and skin is formed.Existing
Think that its cause of disease relates to the many aspects such as heredity, endocrine, immunity, metabolism for medical science, with hyperandrogenism and high islets of langerhans
Element mass formed by blood stasis is principal character, the two definite effect in PCOS falls ill, and it be not immediately clear.Consult traditional Chinese medical science ancient literature, send out
Existing Chinese medical book there is no the relevant name of disease of " polycystic ovarian syndrome ", do not only have dysgenesia according to its clinical manifestation characteristic,
And having Developmental and Metabolic Disorder i.e.: obesity, amenorrhea, hirsutism, infertile etc., according to the relevant discussion of ancient Chinese medicine doctor, primary disease belongs to the traditional Chinese medical science
The category of " amenorrhea " " infertile " " abdominal mass ", sporadically appears in regulating menstruation, asks in the chapter such as heir, seed, and associated name of disease the most just compares
Variation, such as: fertile people's amenorrhea, fertile people are infertile, amenorrhea, unsmooth menorrhea, moon water obstructed, metrorrhagia, loss of fecundity, sterilization, breaks, complete
Not product etc..The etiology and pathogenesis analyzing PCOS according to tcm theory finds, kidney qi virtual loss is the substantially sick of polycystic ovarian syndrome
Machine, the expert such as Penning well, You Zhaoling, Xia Gui city thinks that primary disease is because of congenital kidney water virtual loss, and menses is not enough, multiple condenses institute because of the expectorant stasis of blood
Cause, either deficiency of the kidney yin or insufficiency of kidney-YANG, all by occurring because void causes the pathological change of the stasis of blood, cause punching and appoint stagnation of QI-blood, hinder ovum
Discharging, or kidney yin water in the last of the ten Heavenly stems is not enough, egg development can not be ripe, and phlegm-damp accumulates resistance, and ovary is the change of many capsules sample and arrives infertile;Yang Yueya
Deng it also holds that deficiency of suffering from a deficiency of the kidney, breeding weak, cause follicular development sluggish, the deficiency of vital energy promotes deficiency, causes follicle to be difficult to pass through ovary
And the locking that arrives, therefore cause infertile.Liver is viscus attriguted to wind and wood, easy perverse and unreasonable manner gram soil, then taste are restricted, transporting mistake department, and phlegm-damp is jammed vessels of the uterus born of the same parents
Palace, then can not become pregnant by consolidating semen;Stop up in skin then fat, hirsutism."Fu Qingzhu works on obstetric" is sayed: " woman is kind, and how strongly fragrant bosom is, Liver Channel one
Sick ... difficult in fertility." " married woman advises son class " cloud: " feelings are smooth, then punching times is not filled, then tire is pregnant is not subject to." therefore it is believed that
Depression of liver-QI is the topmost cause of disease of PCOS patient.The spleen being the foundation of acquired constitution, the strong fortune of temper, Xue Xunchang road, blood prosperous and through adjusting.If spleen
Gas virtual loss, the biochemical weary source of QI and blood, or hypoactivity of spleen-YANG, transformation failure of spleen, accumulatively wet raise phlegm, functional activity of QI being not smooth, punching is appointed obstructed, and biochemical function is not
Foot, phlegm-damp adipose membrane bets, accumulates stagnant uterus, then see infrequent menstruation, amenorrhea, infertile etc., or the accumulation of phlegm-damp adipose membrane, pent up internal, impregnate four
Limb, muscle, then obesity, hirsutism.Be thus PCOS with weakness of the spleen and kidney for this, phlegm-damp for mark, insufficiency of the spleen phlegm-damp is the morbidity of PCOS
Crucial.Blood-stasis internal-depression is then the common inducement of this disease, and Thousand Golden Prescriptions points out that " stopping in blood stasis, stagnant blood internal hemorrhage due to trauma " is the former of loss of fecundity
One of because of;Errors in Medicine Corrected is sayed: " vigour is the most empty, can not reach in blood vessel, blood vessel depletion of QI, must stop and be the stasis of blood.Stagnation of blood stasis,
Punching is appointed deficient logical, and the sea of blood can not overflow as scheduled, delayed menstrual cycle;Stagnation of blood stasis in CHONG and REN meridians, blood must not under, then see amenorrhea;In blood stasis
Resistance, escape of blood from meridian and absurd row, it is seen that metrorrhagia;Uterus silt resistance vessels of the uterus then causes infertile.
In sum, PCOS many because suffering from a deficiency of the kidney, stagnation of phlegm-damp, dampness-heat of the liver etc. and cause qi depression to blood stasis, retention of water-damp in the body, metaplasia
Turbid damp, blood stasis dispelling of with the passing of time reducing phlegm, the phlegm-damp stasis of blood ties mutually, and the uterus that is jammed, punching are appointed, and punching is appointed and lost money, dirty
Internal organs function and menoxenia due to dysfunction of CHONG meridian and various clinical symptom occurs, its etiology and pathogenesis always with stagnation of liver-QI, insufficiency of the spleen, kidney asthenia as the principal aspect,
With blood stasis, phlegm-damp, damp and hot for mark, clinical manifestation is common with syndrome of intermingled deficiency and excess.
2 therapeutic rule researchs
To suffer from a deficiency of the kidney, the pathogenesis such as phlegm-damp, blood stasis, yin deficiency, yang deficiency, deficiency of vital energy, use more the kidney invigorating, reduce phlegm, dampness removing, blood stasis dispelling, QI invigorating,
Enrich blood, the therapeutic rules such as warming YANG, kidney deficiency blood stasis type control invigorate blood circulation with nourishing kidney, Chong and Ren Meridians regulating, spleen emptiness and wet sputum type is controlled with drying dampness to eliminate phlegm, reason
Controlled atmosphere warp, a lot of scholar of phlegm and blood stasis thinks that PCOS is mainly relevant with kidney,liver,spleen functional disorder, and Qin Zhu etc. passes through literature research
Finding, the traditional Chinese medical science treats PCOS in recent years
Type is controlled with kidney-replenishing blood-nourishing, dispersing the stagnated live-QI to relieve the stagnation of QI.Chinese traditional treatment focus on benefit, adjust, logical, but PCOS cause of disease complexity pathogenesis changes various,
Clinical manifestation is the most various, and normal many diseases are also seen, therefore should note accompanied symptoms while holding main symptom clinically, needs determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs and differential diagnosis of diseases
Opinion is controlled and is combined, and follows the treatment of women distinctive physiological period, over the course for the treatment of, Nervous and Mental Factors to be paid special attention to simultaneously
Impact, based on long-time conditioning, haste brings no success.Tcm treatment method about PCOS is studied, and clinical doctor passes through clinical observation
The Symptoms of PCOS, uses traditional Chinese medical science organic conception Coryza Treated by Syndrome Differentiation PCOS, sums up various effective Therapeutic Method.Disease
Control the prevailing model of always Chinese medicine diagnosis in conjunction with opinion, for PCOS difference pathogenesis, clinical doctor sums up the kidney invigorating especially and reduces phlegm
The different Therapeutic Method such as method, invigorating kidney, promoting blood circulation method, liver heat removing and kidney replenishing method, clearing away heat-damp and promoting diuresis method, strengthening spleen and nourishing blood tonneau method.Zhong Xiaoling etc. adopt
With the kidney warming nourish blood, blood stasis dispelling tonneau ruling by law treat insufficiency of kidney-YANG, dampness part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels type PCOS patient 30 example, treat 3 cycles, total effective rate
It is 86.67%, higher than the 76.67% of the treatment of matched group clomiphene.Liu Ying etc. are respectively adopted the kidney invigorating and adjust liver method and the kidney invigorating Circulation Resolving Phlegm
Treatment is suffered from a deficiency of the kidney liver energy stagnation type and is suffered from a deficiency of the kidney phlegm-damp type patient 62 example, and result the kidney invigorating adjusts liver method cure-remarkable-effectiveness rate to be 60.46%, and effective percentage is
88.37%;The kidney invigorating Circulation Resolving Phlegm cure-remarkable-effectiveness rate is 52.64%, and effective percentage is 84.21%.Tan Yong etc. are according to using Chinese medicine adjustment menstruation for many years
The experience of circadian rhythm, proposes Chinese medicine and adjusts Zhou Fazhi to treat PCOS, and YIN nourishing postmenstruation is followed in medication, premenstruum YANG invigorating dialectical former
Then, YIN nourishing side, YANG invigorating side are made in the side's of sending medication, and according to physiological activity rule in menstrual cycle, simplify medication by stages, sequential fortune
PCOS menoxenia main symptom, satisfactory effect is treated with YIN nourishing side and YANG invigorating side.Chinese medicine cycling therapy refers to according to the kidney invigorating-invigorate blood circulation
Blood stasis dispelling-the kidney invigorating-promoting blood flow to regulate menstruation, order periodically Selection drug, copy menstrual cycle to treat.Hao Lanzhi uses artificial cycle
Therapy, uses the kidney invigorating Gu Chong, helps the method with blood stasis dispelling regulating menstruation, from intending oral medicinal herb side, is divided into Kaohsiung in 4 stage plus-minus treatment PCOS
Hormone mass formed by blood stasis patient, result fully recovers 30 examples, effective 10 examples, invalid 6 examples;Recovering ovulation rate is 56.52%, and pregnancy rate reaches 41.67%,
Total effective rate 86.96%.Patient 60 example that symbol rosy clouds Artificial menstrual cycle with Chinese herbal medicine therapy for treating polycystic ovarian syndrome is infertile, result is controlled
More 41 examples, effective 12 examples, invalid 7 examples, effective percentage 88.33%.In addition, Chinese traditional treatment PCOS also has acupuncture and moxibustion therapy, Chinese medicine to add
The therapies such as acupuncture therapeutic alliance and plantar reflecting region massage treatment, all obtain preferable curative effect in clinic.
3 side's medicine applied researcies
The most the more commonly used by side medicine application for the treatment of PCOS, mainly include that compound recipe adds and subtracts treatment, classical prescription treatment, Chinese patent medicine
Treatment, famous physician face card experience.Li Qiaofen etc. are by dialectical for PCOS 4 types that are divided into: spleen emptiness and wet sputum type, control with invigorating the spleen and benefiting QI, eliminate the phlegm logical
Warp, foshousan plus-minus closes with grey attached expectorant ball of leading in side;Kidney-yang deficiency type, controls with the kidney warming drying dampness to eliminate phlegm, and side's Gui-shen pill is added and subtracted;The stagnation of QI
Phlegm retention, controls with depressed liver-energy dispersing and QI regulating, promoting the circulation of QI and reducing phlegm, and side's XIAOYAO POWDER is added and subtracted;Intermingled phlegm and blood stasis type, controls with blood circulation promoting and blood stasis dispelling, drying dampness to eliminate phlegm,
Side's Ramulus Cinnamomi Poria pill closes DANGGUI SHAOYAO SAN plus-minus.Sang Xia uses classical prescription Decoction of Gentiana for Purging the Liver-fire plus-minus treatment Liver Channel stagnated fire type PCOS
Treat, within 3 months, be 1 course for the treatment of, treat altogether 1 ~ 2 course for the treatment of, observe clinical symptoms before and after treatment, menstrual cycle and serum FSH, LH,
E2, T level changes, and result serum Lh, T, LH/FSH lower punching, 25 examples before the most relatively treating, and clinical observation is evident in efficacy.Must justice
Chastity etc. gives 60 example patients with polycystic ovary syndrome kidney tonifying Huatan Formulas and controls
Fall (P < 0.01);3 month to dates recover to pass through 51 examples, and clinical efficacy is good.Xie Jinghong etc. use the many capsules of Chinese medicine preparation
Drink (Semen Cuscutae, the Radix Paeoniae Alba, Herba Epimedii, Radix Bupleuri etc.) treatment PCOS suffers from a deficiency of the kidney patients with TCM liver depression 30 example, and 6 months effective percentage for the treatment of are continuously
86.7%, pregnancy rate is 62.5%, and the moon, improved effective percentage was 83.3%, before and after treatment difference be respectively provided with statistical significance (P <
0.05).Liu Yun etc. are found by clinical observation, danzhi xiaoyao pills can improve PCOS companion IR anovulatory sterility patient's ovulation rate and
Pregnancy rate, and tcm syndrome, relatively single use of western medicine can be significantly improved there is clear superiority.Chen Hehong etc. sum up the good Experience in Treating of Qin Yue
PCOS experience, selects five ability Hydrargyri Oxydum Rubrum soup, Longdan Xiegan Tand Jiawei, red Cape jasmine free and unfettered the patient of different pattern of syndrome according to physiological period respectively
Distant dissipate add taste, Gexia Zhuyu Tang adds taste, grey attached Daotan Tang adds taste, three sub-SANHUANG menstruation-regulating soups, removing blood stasis Dang Bao regulating menstruation Tonga taste, pink
SIWU TANG adds side's medicines such as taste and treats, and sets up man-made drugs's cycle, and clinical efficacy is notable.
4 modern studies
Along with the development of medical science, a lot of scholars have done for the decoction for the treatment PCOS mechanism of action and have probed into further.Tao Lili etc. lead to
Crossing research to find, plus-minus Decoction of Gentiana for Purging the Liver-fire can obviously improve Liver Channel stagnated fire type PCOS patient's hyperandrogenism symptom and endocrine
Situation, it is possible to be effectively improved the clinical manifestation of PCOS, the islets of langerhans of Liver Channel stagnated fire type PCOS patient can be corrected the most to a certain extent
Element opposing situation, for may play the thecacells pigment of pivotal role in Liver Channel stagnated fire type PCOS develops
P450C17 enzymatic activity, plus-minus Decoction of Gentiana for Purging the Liver-fire also has dual regulation effect, and it can be changed by the activity reducing P450C17 enzyme
Kind hyperandrogenism, thus play the effect for the treatment of PCOS.Yu Anqi is it has also been found that soothing the liver pathogenic fire purging Chinese medicine can obviously improve Liver Channel
Stagnated fire symptom, reduces free testosterone, androstenedione, thus treats hyperandrogenism, can improve body peripheral tissues to islets of langerhans
Element sensitivity, improves insulin resistance condition, reduces the serum leptin level raised, and by improving hypothalamo pituitary
The function of hypothalamic pituitary ovarium axis, reduces patient LH/FSH, LH, thus improves ovary ovulatory dysfunction, adjusts menstrual cycle, makes part not
Pregnant patient becomes pregnant.The research such as Xu Lianwei etc., Wen Jiong shows that invigorating kidney, promoting blood circulation, blood stasis dispelling prescription treatment PCOS can pass through increasing serum SHBG
With reduce serum FAI, reduce androgen levels, improve lipid metabolism, improve insulin level, and achieve preferable curative effect.
Zhou Lulu research finds that damp abundance due to splenic asthenia type polycystic ovarian syndrome can effectively be treated by invigorating the spleen to clear away damp pathogen medicine, it is possible to improve in serum
Hormonal readiness, make the clinical symptoms of patient and sign well be improved.Zhai Jun etc. find Jianpi Bushen associating diformazan
Biguanide can obviously reduce metabolic abnormalities of obese women with obese polycystic ovary syndrome LH, T level, improves the sensitivity of insulin, reduces blood fat water
Flat, reduce metformin side effect, improve patient compliance, the especially improvement to blood fat and be substantially better than metformin alone
Group.Lin Min research is thought and is used the Chinese medicine of dispelling phlegm and eliminating dampness, can reduce phlegm-dampness constitution fat generation in the patient, change lipid generation
Thank, reduce blood viscosity, improve apolipoprotein content in blood, thus reach dispelling phlegm and eliminating dampness, lively atmosphere blood, the purpose of Disperse hepatic depression,
Phlegm-damp, blood stasis gone, and QI and blood passages through which vital energy circulates is unobstructed, rushes wantonly two arteries and veins and adjusts and reach, then the light body of body is good for, and menses can be able at present.White horse with a black mane
Generation is deposited research and is also indicated that TCM Recipe medicine can reduce T, FT, A, thus can be used for treating hyperandrogenism, adjusts LH/FSH ratio
Example, nurses one's health Liver and kidney, adjusts menstrual cycle, makes equilibrium between yin and yang make part infertile patient become pregnant.
5 brief summaries
In sum, for a long time PCOS the cause of disease and treatment all in the exploratory development stage, be appreciated that, in middle treatment
Applying of all sides of Chinese medicine under then instructing can substantially regulate all cards of PCOS in clinic, but due to for TCM Therapy
Related Mechanism and effect link research be scarcely out of swaddling-clothes, in terms of mechanism elaboration shortage Unified Explanation.Along with medical science
Development, explores Chinese medicine PCOS preferred plan and verifies that its Related Mechanism will be becoming of future studies Chinese traditional treatment PCOS
To.
Medicine of the present invention is the most meticulously to develop through inventor, is mainly used in treating polycystic ovarian syndrome.After deliberation
Showing, medicine of the present invention has preferable therapeutic effect to polycystic ovarian syndrome.
In medicine of the present invention, the Ji Yuan of crude drug is as follows:
Rosa bella Rehd et wils is Rosaceae gul Mei QiangwieRosa bella Rehd. et WilsFruit.
Yellow calamite is Berberidaceae berberis Huang calamiteBerberis amurensis Rupr.Root and stem, branch.
Summary of the invention
It is an object of the invention to provide the medicine of a kind of Rosa bella Rehd et wils and yellow calamite.
It is a further object of the present invention to provide the preparation method of this medicine.
Present invention also offers the quality determining method of this medicine.
Present invention also offers the pharmaceutical applications of this medicine.
It is an object of the invention to be realized by the following manner:
A kind of medicine is made up of the raw material of following weight portion: Rosa bella Rehd et wils 1~2 weight portion, yellow calamite 1~2 weight portion.
This medicine is preferably made up of the raw material of following weight portion: Rosa bella Rehd et wils 1 weight portion, yellow calamite 2 weight portion.
This medicine is preferably made up of the raw material of following weight portion: Rosa bella Rehd et wils 2 weight portion, yellow calamite 1 weight portion.
This medicine is preferably made up of the raw material of following weight portion: Rosa bella Rehd et wils 1 weight portion, yellow calamite 1 weight portion.
Described medicine can be prepared as tablet, pill, powder, hard capsule, soft capsule, granule, oral liquid.
Described medicine is adopted and is prepared with the following method: takes Rosa bella Rehd et wils, yellow calamite, mixing, adds the water logging of 3~15 times amount
Steeping 0.5~2 hour, decoct 0.5~2 hour, decoct 2~4 times, each 0.5~2 hour, extracting solution merged, and filtered, and filtrate is dense
Contracting, dry, pulverize into fine powder, adds adjuvant, mixing, loads hard capsule, to obtain final product.
Described medicine preferably employs following method to be prepared: takes dry Rosa bella Rehd et wils, yellow calamite, adds 11 times amount for the first time
Water soaking 1 hour, decocts 1 hour, and second time adds 4 times amount soak by water 1 hour, merges decocting liquid, filters, and filtrate concentrates, and is dried,
It is ground into fine powder, sieves, mixing, load hard capsule, to obtain final product.
Detection with the following method adopted by described medicine: use high performance liquid chromatography to carry out the assay of euscaphic acid Jacaric acid:
(1) chromatographic condition: use HypersilDs chromatographic column;Flowing phase: ratio is the acetonitrile-water of 20~40:60~80;Detection
Wavelength: 190~210nm;Column temperature: 15~25 DEG C;Flow velocity: 0.5~1.5mL min-1;Sample size: 5~20 μ L;
(2) prepared by reference substance solution: it is appropriate that precision weighs the euscaphic acid Jacaric acid reference substance being dried to constant weight, adds methanol dissolving and makes comparison
Product solution;
(3) preparation of need testing solution: precision weighs medicine of the present invention, adds methanol, is heated to reflux, extracting solution reflux solvent is the denseest
Being reduced to do, residue is dissolved in water, and extracts with the shaking of water saturated n-butyl alcohol, merges n-butanol extracting liquid, washs with ammonia solution, just
Butyl alcohol extraction liquid recycling design is to dry, and residue adds methanol and dissolves, and shakes up, and filters, takes filtrate, obtain need testing solution;
(4) measure: precision measures above-mentioned need testing solution, reference substance solution each 5~20 μ L respectively, inject high performance liquid chromatography
Instrument, detects.
Described medicine preferably employs the detection of following method: use high performance liquid chromatography to carry out measuring containing of euscaphic acid Jacaric acid
Fixed:
(1) chromatographic condition: use HypersilDs chromatographic column;Flowing phase: ratio is the acetonitrile-water of 30:70;Detection wavelength:
200nm;Column temperature: 20 DEG C;Flow velocity: 1.0mL min-1;Sample size: 10 μ L;
(2) prepared by reference substance solution: precision weighs 80 DEG C and is dried to the euscaphic acid Jacaric acid reference substance of constant weight appropriate, adds methanol dissolving and makes
Every 1mL reference substance solution containing 0.2mg;
(3) preparation of need testing solution: precision weighs medicine 10g of the present invention, adds methanol 40mL, is heated to reflux 4h, and extracting solution returns
Stream solvent is also concentrated to dryness, and the residue 10mL that adds water dissolves, and extracts 5 times with the shaking of water saturated n-butyl alcohol, each 20mL, and merging is just
Butyl alcohol extraction liquid, washs 3 times with ammonia solution, each 15mL, and n-butanol extracting liquid recycling design is to dry, and residue adds methanol and dissolves also
It is transferred in 10mL volumetric flask, adds methanol to scale, shake up, filter, take filtrate, obtain need testing solution;
(4) measure: precision measures above-mentioned need testing solution, each 10 μ L of reference substance solution respectively, inject high performance liquid chromatograph, enter
Row detection.
Described medicine can be used for preparation treatment polycystic ovarian syndrome, the medicine of ovarian cyst or health product.
Experiment one: the medicine of the present invention impact on Model of Polycystic Ovarian Syndrome rat
This experimentation uses progestogen and HCG associating molding method to prepare rats with polycystic ovary syndrome model, before comparing medication
Rear hormone serum level changes, to providing experimental data and effect side's medicine for traditional Chinese medical herbal treatment PCOS.
1 experiment material
1.1 laboratory animal
24d age teenage SD female rats, body weight 30 ~ 40g, Heilongjiang University of Chinese Medicine's Experimental Animal Center provide.
1.2 medicines and reagent
Medicine of the present invention: prepare according to the embodiment 1 in description of the invention detailed description of the invention;
Drugs compared first: prepare according to the embodiment 2 in description of the invention detailed description of the invention;
Drugs compared second: prepare according to the embodiment 3 in description of the invention detailed description of the invention;
Metformin: dissolve with distilled water, after converting by people's Mus weight ratio, with 0.018g/d dosed administration.
Test kit: Beijing North great achievement Development Co., Ltd, lot number: RT110371.
2 experimental techniques
2.1 experiment packets
60 rats are randomly divided into medication therapy groups of the present invention, drugs compared first group, drugs compared second group, metformin comparison
Group, model control group and negative control group, totally 6 groups, often 10 rats of group.
2.2 experimental technique
0.5mg LNG day 1 subcutaneous injection, when 27d age, add with 2 subcutaneous injections of HCG 1.5IU day, altogether
Injection 21d.
After modeling success, (1) medicine of the present invention group: give medicine 1.8g/d of the present invention;(2) drugs compared first group: give
Drugs compared first 1.8g/d;(3) drugs compared second group: give drugs compared second 1.8g/d;(4) metformin group: give diformazan
Biguanide 0.018g/d.Every day 1 gavage, successive administration 15d.
3 experimental results
In each treated animal serum, FSH, LH, T Concentration Testing result, is shown in Table 1-l.Negative control group and the serum of model control group
All there were significant differences for the content of FSH, LH and T (P < 0.05), prompting modeling success.
After treatment, in medicine group of the present invention and negative control group serum FSH, the content of LH and T there was no significant difference (P >
0.05), Drug therapy of the present invention is pointed out can to affect the level of FSH, LH and T of PCOS patient so that it is close to normal, and to contrast
The effect of medicine first group and drugs compared second group is the best.
In table 1-1 each treated animal serum FSH, LH, T concentration (± S)
Note: compare with model control group, #P < 0.05, ##P < 0.01;Compare with negative control group, ☆ P > 0.05.
4 discuss
Polycystic ovarian syndrome clinical manifestation is the endocrinic syndrome of polymorphism, with Hyperandrogenism and chronic anovulation for facing
Bed principal character, is to cause one of modal reason of women at fertile age menoxenia.Its Pathophysiology feature generally acknowledged is: male
Hormone generates too much, and high LH is with normal or low-level FSH, hyperinsulinemia-insulin resistant.Polycystic ovarian syndrome
LH and T of rat model substantially relatively negative control group raises, and FSH is slightly lower, is because the hypophysis of patients with polycystic ovary syndrome
GnRH sensitivity is increased, secretion excess LH and ovary are formed as androgen the cytochrome (cytochromep-of enzyme
Functional disorder 450c17), causes stroma of ovary, thecacells to produce excessive androgens.Excessive androgen suppression ovum in ovary
Soak ripe, cause developmental follicular atresia, it is impossible to form dominant follicle, so that the normal secretions interrupt of estrogen, but
A lot of little follicles still secrete estrogen.The estradiol effect of the certain level of the estrone of continuous release and the secretion of ovary little follicle
In hypothalamus and hypophysis, the secretion to LH is positive feedback, makes LH secretion amplitude and frequency increase, and LH is continual high levels, and FSH
Level of relative reduces.
5 conclusions
Medicine of the present invention may interfere with the hormonal readiness of patients with polycystic ovary syndrome, thus reaches to cure the purpose of this disease.Especially
It is that the action effect of medicine of the present invention is substantially better than drugs compared first and drugs compared second, and two kinds of medicines in medicine of the present invention are described
Compatibility between taste is superior, indispensable, and the combination between two kinds of flavour of a drug creates obvious synergistic function, creates one
The technique effect adding one more than two.
Experiment two: the effect observation of Drug therapy 40 example polycystic ovarian syndrome of the present invention
The main mode using oral promoting ovulation drug of the treatment of doctor trained in Western medicine polycystic ovarian syndrome (PCOS) in the past, but along with medication
The prolongation of time, there is difficult gestation, the phenomenon of easily miscarriage in patient.In recent years, operative treatment, peritoneoscope coagulation have been carried out clinically
The modes such as punching art, Effect value must be affirmed, but the wound causing women is the biggest.Research worker application medicine pair of the present invention
PCOS patient treats, and achieves good effect.Now report is as follows.
1. data and method
1.1 clinical data
In patients with polycystic ovary syndrome 75 example that my institute is medical during in March, 2015 in February, 2016, all meet " department of obstetrics and gynecology
Learn " in about the diagnostic criteria of polycystic ovarian syndrome.Primary symptom: irregular menstruation, occurs that hypomenorrhea or amenorrhea are infertile;Laboratory
Check: interstitialcellstimulating hormone (ICSH) (LH)/FSH (FSH) > 3 and (or) testosterone (T) > 2.2nmol/L and (or) androstene
Diketone (A) > 9.0nmol/L.Ultrasound diagnosis: side or bilateral ovaries increase, polycystic change.
Rejecting standard: the androgen that 1. other endocrinopathyes cause raises;2. the infertility that other factors cause;③
Psychological problem or the patient of cognitive dysfunction;Within the nearlyest 3 months, took the endocrine medicine of impact or contraceptive person;5. merge
The organic diseases such as severe cardiac, kidney, liver.
Age 23~36 years old, the course of disease 1~8 years.Wherein menoxenia 61 example, infertile person 58 example, overweight people 31 example.
Different according to Therapeutic Method, it is divided into observation group and matched group, matched group 35 example, observation group 40 example.2 groups of patient's years
Age, the course of disease compare no significant difference (P > 0.05), have comparability.
1.2 Therapeutic Method
Matched group employing regular western medicine treatment spironolactone sheet 40mg, 2 times/d, successive administration 20d.Diformin tablet 0.5g, 3
Secondary/d, to drug withdrawal during normal ovulation.Clomiphene capsule 50mg/d, is used in conjunction 5d.Vitamin C 200mg, 3 times/d, is used in conjunction 20d.
Observation group adds with medicine of the present invention (with reference in description of the invention detailed description of the invention on the basis of matched group
Prepared by embodiment 4), each 2, every day 2 times, a point morning and evening takes for 2 times.From menstrual cycle the 7th day, take 3d, drug withdrawal continuously
1d.The course for the treatment of 3 menstrual cycle.
1.3 observation index
Treatment 2 groups of patient clinical symptom variation of fore-and-aft observing, lab testing follicule-stimulating hormone (FSH) (FSH), lutropin (LH),
Testosterone (T) level changes.
Ultrasound diagnosis ovary becomes with uterine blood flow:
RI=(peak systolic velocity-blood flow speed at the end of vasodilation)/peak systolic velocity;
Minimum blood flow rate in PI=(peak systolic velocity-cardiac cycle) time average of/peak veloity,PV.
1.4 efficacy assessment standard
With reference to the standard of polycystic ovarian syndrome in Ministry of Public Health " new Chinese medicine guideline of clinical investigations ":
Recovery from illness: continuous 3 months menstruation recovery normal cycles after drug withdrawal, menstrual period, blood volume are all normal, recover normal ovulation, BBT two-phase
Or gestation, tcm syndrome therapeutic index >=90%;
Effective: after treatment, menstruation is close to normal cycle (within 40d), and blood volume is normal, menstrual period 8~10d, 90% > Syndrome in TCM
Wait therapeutic index >=66.67%;
Effective: menstrual onset 1 time in treating 3 months, improve in various degree before relatively treating in blood volume, menstrual period, 66.67% > Syndrome in TCM
Wait therapeutic index >=33.33%;
Invalid: treatment 3 months continuously, menstrual cycle has no improvement, tcm syndrome therapeutic index < 33.33%.
1.5 statistical method
Use SPSS 15.0 statistical software that data are carried out statistical analysis, enumeration data and measurement data and be respectively adopted χ2Inspection
Test, t checks.For difference, there is statistical significance with P < 0.05.
2 results
2.1 2 groups of patient's comparitive study
Observation group's treatment total effective rate is 92.5%, and matched group total effective rate is 71.4%, and difference has statistics
Meaning (χ2=5.784, P < 0.01), it is shown in Table 2-1.
Therapeutic effect contrast (example) of 2 groups of patients with polycystic ovary syndrome of table 2-1
After 2.2 2 groups of patient treatments, induced ovulation, recovery ovulation, Pregnancy compare
Observation group's follicle maturity rate, recovery ovulation, pregnancy rate are all significantly better than matched group (χ2=9.099,6.857,12.538, P
< 0.01), it is shown in Table 2-2.
After 2 groups of patients with polycystic ovary syndrome treatments of table 2-2, induced ovulation, Pregnancy compare [ example (%) ]
Hormonal readiness change before and after 2.3 treatments
Compared with before treatment, LH, T and LH/FSH all decrease before relatively treating.After treatment, each hormonal readiness phase ratio between group
Different statistically significant (t=5.324,6.254,3.413,13.580, P < 0.05), are shown in Table 2-3.
The change of hormonal readiness before and after 2 groups of patients with polycystic ovary syndrome treatments of table 2-3
3 discuss and conclusion
There is no saying of " polycystic ovarian syndrome " in traditional medicine, it is subordinate to categories such as " amenorrhea " " delayed menstrual cycle " " infertile ".In
Doctor thinks, " going out all kidneys through water ", in place of i.e. kidney is store essential substances, is the essential condition risen of feminine menstrual.Deficiency of kidney-QI, the stagnant blood of deficiency and coldness
Being primary disease basis, QI and blood expectorant is turbid for folder pathogenesis of holding concurrently.Suffer from a deficiency of the kidney can not rising part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels body fluid, insufficiency of the spleen can not transmitting and distributing the fluids, body fluid water is wet
Gathering and form expectorant, phlegm-damp of suffering from a deficiency of the kidney is mingled with, and damages negative and positive mutually.Then induction "-uterus is appointed in kidney-sky decyl-punching " Reproductive Axis dysfunction, i.e.
PCOS。
The growth promoter of ovum is by hormone regulating and controllings such as FSH, LH.FSH acts on ovary, promotes developing into of primordial follicle
Ripe.When FSH concentration deficiency in follicular fluid, mitosis is obstructed, and follicle cannot continue to grow.Having research to point out, FSH level exists
In the selection of dominant follicle most important.LH is the characteristic change that PCOS patient lab checks extremely, is also reproduction merit
The basic reason of energy obstacle.Internal too high LH can promote that thecacells, Interstitial cell produce a large amount of androgens, and converts
For estrone.Estrone can upset the formation at LH peak in menstrual cycle, affects maturation and the discharge of follicle.This research shows, observation group
LH/FSH ratio after treatment significantly reduces, and T hormonal readiness declines, and contributes to the growth of mature follicle and increases intrauterine
The growth of film.Prompting, medicine of the present invention can warming and recuperating the kidney-YANG, increase Progesterone Secretion, strengthen luteal function, irregular menstrual rises,
Good environment is built for Embryo implantation.Kidney yin must be supported, and kidney yang must be changed, and benefiting essence-blood is appointed originally with Gu Chong, therefore essential substance for reproduction is abundant.
Data show, observation group's treatment total effective rate is 92.5%, and simple western medicine only 71.4%.Additionally, observation group's recovery ovulation situation,
Pregnancy rate is significantly better than matched group, say, that PCOS patient is ovulated by medicine of the present invention, gestation is the most useful.
Experiment three: the experimentation of Drug therapy ovarian cyst of the present invention
Ovarian cyst (OvarianCyst, OC) is one of common benign tumor of modern gynecological, accounts for the 75% of ovarian tumor.It
Refer to that ovary is internally generated Cystic lesions, Non-cancerous and tumprigenicity two class can be divided into, be equal to the traditional Chinese medical science " abdominal mass " " accumulation " " intestinal
Deep " etc. sick category, be mainly in the young women of 20~50 years old, sickness rate accounts for the 15% of the women of child-bearing age.During research worker is used
Theory of medicine inquires into basic pathogenesis and the Therapeutic Principle of OC, it is believed that this disease many ignorance in menstrual period or puerperal because of women nurses one's health, because of seven
Invade in the heresy of feelings internal injury or six climate exopathogens, visceral dysfunction, raw in causing turbid damp phlegm retention, stagnation of blood stasis vessels of the uterus, accumulation with the passing of time shape
Become cyst.Its pathogenesis core is stagnation of liver-QI with deficiency of the spleen, phlegm and blood stasis.Treat suitable invigorating the spleen and relieving depression of liver-QI, dampness removing reduces phlegm, blood circulation promoting and dispersing pathogen accumulation.
Medicine of the present invention has extraordinary therapeutic effect to polycystic ovarian syndrome, and research worker is predicted, medicine of the present invention
Ovarian cyst also should be had certain therapeutic effect, the most just carried out trial row experimentation, observe medicine of the present invention
On interleukin-6(IL-6 in OC rat model blood), estradiol (E2), progesterone (P) content impact.
1 material
1.1 experimental animal
SPF level healthy adult female wistar rat 75, at two monthly ages, body weight (200 ± 10) g, experimental animal is by Heilungkiang
Medical pharmaceutical university Experimental Animal Center provides.
1.2 medicines and preparation
Medicine of the present invention: prepare with reference to the embodiment 1 in description of the invention detailed description of the invention.It is condensed into every milliliter respectively to contain
Crude drug 1, two kinds of medicinal liquids of 2g, as low dose group and high dose group.Put 4 DEG C of preservations in refrigerator.
Positive control drug: Ramulus Cinnamomi Poria pill (poplar Wenshui, Shanxi pharmaceutical Co. Ltd, traditional Chinese medicines quasi-word Z14020791), every ball
Weight 6g.
1.3 main agents
10% chloral hydrate, 10% mustard oil, paraffin oil, injection normal saline, medical povidone iodine.Operating theater instruments a set of (scalpel,
Big staight scissors, big curved scissors, tissue clamps, ophthalmic tweezers, mosquito forceps, stitching needlework, aseptic cotton balls, medical gloves, disposable syringe
Deng).
1.4 main equipment
Full-automatic chemiluminescence apparatus, ADVIAXP(Siemens);(biological limited public affairs are built up in Nanjing to gonadal hormone test kit
Department);Rat, IL-6ELISA, ERC003(Xin Bosheng bio tech ltd);Freezing microtome, Finesse325(Britain three
Bio tech ltd);Analytical balance, BS110S(Beijing Sai Duolisi balance company limited);White mouse complete set cage (Soviet Union
Tremble with fear mountain metal product plant in state).
2 methods
2.1 test packets
Animal is randomly divided into 5 groups, often group 15.It is respectively normal group, model group, Ramulus Cinnamomi Poria pill group, low dose of medicine of the present invention
Amount group, medicine high dose group of the present invention.
2.2 modeling method
With reference to the refined chastity of Wesselmann(king. practical obstetrics and gynecology [M]. Beijing: People's Health Publisher, 2000:707) cause for big
Mus " ovarian cyst " model, after using 10% chloral hydrate abdominal cavity (0.35/100g) injecting anesthetic, making rat is dorsal position, fixing
On dissecting table, Ventral Midline shaves off Mus hair routine disinfection, makees the otch of 1.5cm length and vertical direction in Ventral Midline, cuts
Being pubic symphysis at 0.5cm above mouth lower end, herein, chorista and the liparitosis held, find defeated ovum on rear side of bladder
Pipe, finds out left ovary along ampulla of uterine tube, notes by the mustard oil (the mustard oil paraffin oil of 95% dilutes) of 0.1mL10%
Enter ovary, with soft wax, injection pinprick is sealed, prevent overflow of drug fluid.Layering suture operation otch, terminal disinfection otch, by white mouse
Put back in cage.The acute congestion edema of internal organs can be caused after general injection mustard oil 2h, occur that inflammatory reaction forms cyst.At note
Win rats with left ovary after penetrating 2h, after 10% formaldehyde fixes 48h, ethanol serial dehydration, carry out the frozen section system of 15 μm
Make, carry out HE dyeing.Form at two groups of ovaries of low power Microscopic observation, it can be seen that after injection mustard oil, the ovary of rat is obvious
Congested, edema.With ovarian cyst > 10mm is for modeling successfully.
2.3 medication
Modeling success each group random assortment completes i.e. to start to be administered.Medicine high dose group of the present invention, medicine low dose group of the present invention
Gavage medicine decocting liquid of the present invention respectively, be respectively equivalent to containing crude drug 50g kg-1·d-1With 25g kg-1·d-1;Cassia twig tuckahoe
Ball group gavages isometric Ramulus Cinnamomi Poria pill suspension;Normal group and model group fill with isometric normal saline.All press for each group
0.25mL·10g-1·d-1Gavage.1 time/d, continuous 6 weeks.
2.4 method of drawing material
After being grouped, blood will be taken by rat tail, put in labelling clearly EP pipe.Gavage uses same method to take after 6 weeks
Blood.Measure before and after often group processes IL-6 and the content of gonadal hormone (estradiol, progesterone) in rat blood.
2.5 statistical procedures
Measured data acquisition statistic software SPSS 13.0 is analyzed, and measurement data uses (sx ±) to carry out statistics and describes.Warp
After homogeneity test of variance, between each group, carry out the analysis of variance F.Comparing between group and check with t, P < 0.05 represents that difference has statistics
Meaning.
3 results
Comparing with Normal group, IL-6 and the content of gonadal hormone (estradiol, progesterone) in model group are significantly raised, are shown in Table 3-
1。
IL-6, estradiol, the content of progesterone in rat blood serum is respectively organized before table 3-1 treatment
After medicine of the present invention and Guizhi Fuling Pills in Treating, it was observed that big in Ramulus Cinnamomi Poria pill group of IL-6, estradiol, progesterone
Content in Mus blood all decreases (P < 0.05), and IL-6, estradiol, progesterone medicine high dose group of the present invention, this
The content in rat blood in bright medicine low dose group the most substantially reduces (P > 0.05), is shown in Table 3-2.
IL-6, estradiol, the content of progesterone in rat blood serum is respectively organized after table 3-2 treatment
4 conclusions
This experimentation shows, medicine of the present invention can not reduce the level of IL-6, it is impossible to suppression local fibroblasts hypertrophy, fibre
Fibrillarin is formed and collagen deposition, can not alleviate ovarian cyst focus inflammatory adhesion and fibrosis, the growth to ovarian cyst
There is no inhibitory action, so, drugs on ovarian cyst of the present invention is without therapeutical effect, it is impossible to make cyst atrophy.
Experiment four: the quality determining method research of medicine of the present invention
1 instrument and reagent
1.1 instrument
High performance liquid chromatograph (examine for Agilent110 high performance liquid chromatograph and work station, G1311Aquat pump by G1314 ultraviolet
Survey device).
1.2 reagent
Euscaphic acid Jacaric acid reference substance (China pharmaceutical biological product calibrating academy);Chinese medicine composition of the present invention;Chinese crude drug (Harbin Pharmaceutical Group
The people provide with safe chain pharmacy);Methanol (chromatograph alcohol, biochemistry work auxiliary reagent factory, Shanghai);Other reagent are analytical pure.
2 methods and result
2.1 prescription
Rosa bella Rehd et wils 500g, yellow calamite 500g.
2.2 preparation
Take dry Rosa bella Rehd et wils 500g, yellow calamite 500g, add 11000mL water soaking 1 hour for the first time, decoct 1 hour, second
The secondary 4000mL that adds, decocts 1 hour, merges decocting liquid, filters, and filtrate concentrates, and is dried, to obtain final product.
The assay of 2.3 euscaphic acid Jacaric acids
2.3.1 HPLC chromatogram condition
Use HypersilDs(4.0mm × 125mm, 5 μm) chromatographic column;Flowing phase: ratio is the acetonitrile-water of 30:70;Detection ripple
Long: 200nm;Column temperature: 20 DEG C;Flow velocity: 1.0mL min-1;Sample size: 10 μ L;Under this chromatographic condition, reference substance and sample color
Spectral peak is good, noiseless to measuring without Rosa bella Rehd et wils negative control.
2.3.2 the preparation of reference substance solution
Precision weighs 80 DEG C and is dried to the euscaphic acid Jacaric acid reference substance of constant weight appropriate, adds methanol and makes every 1mL solution containing 0.2mg.
2.3.3 need testing solution and the preparation of negative controls
Precision weighs medicine 10g of the present invention, adds methanol 40mL, is heated to reflux 4h, and extracting solution reflux solvent is also concentrated to dryness, residue
The 10mL that adds water dissolves, and extracts 5 times with the shaking of water saturated n-butyl alcohol, each 20mL, merges n-butanol extracting liquid, wash with ammonia solution
Washing 3 times, each 15mL, n-butanol extracting liquid recycling design is to dry, and residue adds methanol and dissolves and be transferred in 10mL volumetric flask, adds
Methanol, to scale, shakes up, and filters, takes filtrate and get final product;The negative controls of Rosa bella Rehd et wils, same method is not separately contained in the preparation of prescription ratio
Make negative controls.
2.3.4 the drafting of standard curve
Precision weighs 80 DEG C and is dried to the euscaphic acid Jacaric acid reference substance of constant weight appropriate, makes 10.4 with methanol, and 20.8,41.6,83.2,
166.4μgmL-1The solution of series concentration, precision measures each 10 μ L of above-mentioned 5 kinds of strength solution respectively, injects high performance liquid chromatograph
It is measured.
Carrying out linear regression with peak area ratio and concentration, obtaining regression equation is: A=21.2763C-0.1391, r=
0.9999.Show that euscaphic acid Jacaric acid is at 10.4~166.4 μ gmL-1In good linear relationship in concentration range.
2.3.5 stability test
Accurate absorption need testing solution 10 μ L, respectively at 0,1,2,4,8h sample introduction, and calculate euscaphic acid Jacaric acid content.RSD in result 8h
For 0.45%(n=5).Show that sample solution is stable in 8h.
2.3.6 replica test
By 5 parts of need testing solution preparation method parallel processing sample, measure euscaphic acid Jacaric acid content in accordance with the law and calculate.Result records Flos Rosae Multiflorae
Acid average content is 0.12mg g-1, RSD is 1.3%.
2.3.7 Precision Experiment
Accurate euscaphic acid Jacaric acid reference substance solution of drawing, repetition sample introduction 5 times, measure peak area in accordance with the law.Result RSD is 0.23%(n=5).
Show that precision is preferable.
2.3.8 response rate experiment
Precision weighs 6 parts of the sample of the same lot number of known euscaphic acid Jacaric acid content, adds appropriate by high, medium and low concentration precision respectively
Euscaphic acid Jacaric acid reference substance solution, by under sample determination item operate, measure in accordance with the law, calculate the response rate.Result average recovery rate is
100.3%, RSD are 0.45%(n=5).
2.3.9 sample size measures
Measuring reference substance solution respectively and need testing solution is appropriate, filter with microporous filter membrane, each sample introduction 10 μ L, by above-mentioned chromatostrip
Part measures 3 batch samples, parallel assay 5 times.By external standard method with the content of calculated by peak area need testing solution euscaphic acid Jacaric acid.This product contains rose
Common vetch acid should be and indicates the 95%~105% of content, contains in terms of euscaphic acid Jacaric acid by every 1g sample, must not be less than 0.12mg.3 batch sample content divide
Wei 100.8%(RSD=1.2%), 101.7%(RSD=1.3%), 99.2%(RSD=1.1%).
Detailed description of the invention:
Embodiment 1: medicine of the present invention
Prescription: Rosa bella Rehd et wils 50g, yellow calamite 50g
Preparation method: take dry Rosa bella Rehd et wils 50g, yellow calamite 50g adds 1100mL water soaking 1 hour for the first time, decocts 1 little
Time, second time adds 400mL, decocts 1 hour, merges decocting liquid, filters, and filtrate concentrates, and is dried, obtains medicine of the present invention.
Embodiment 2: drugs compared first
Prescription: Rosa bella Rehd et wils 100g
Preparation method: take dry Rosa bella Rehd et wils 100g, adds 1100mL water soaking 1 hour for the first time, decocts 1 hour, for the second time
Adding 400mL, decoct 1 hour, merge decocting liquid, filter, filtrate concentrates, and is dried, obtains drugs compared first.
Embodiment 3: drugs compared second
Prescription: yellow calamite 100g
Preparation method: take dry yellow calamite 100g, adds 1100mL water soaking 1 hour for the first time, decocts 1 hour, and second time adds
400mL, decocts 1 hour, merges decocting liquid, filters, and filtrate concentrates, and is dried, obtains drugs compared second.
Embodiment 4: pharmaceutical hard capsule agent of the present invention
Drug prescription: Rosa bella Rehd et wils 500g, yellow calamite 500g
Preparation method: take dry Rosa bella Rehd et wils 500g, yellow calamite 500g, add 11000mL water soaking 1 hour for the first time, decoct 1
Hour, second time adds 4000mL, decocts 1 hour, merges decocting liquid, filters, and filtrate concentrates, and dry, pulverize into fine powder, adds auxiliary
Material, mixing, load hard capsule, make 1000..
Use high performance liquid chromatography that euscaphic acid Jacaric acid carries out assay:
(1) chromatographic condition: use HypersilDs chromatographic column;Flowing phase: ratio is the acetonitrile-water of 30:70;Detection wavelength:
200nm;Column temperature: 20 DEG C;Flow velocity: 1.0mL min-1;Sample size: 10 μ L;
(2) prepared by reference substance solution: precision weighs 80 DEG C and is dried to the euscaphic acid Jacaric acid reference substance of constant weight appropriate, adds methanol and makes often
The 1mL solution containing 0.2mg;
(3) preparation of need testing solution: precision weighs medicine 10g of the present invention, adds methanol 40mL, is heated to reflux 4h, and extracting solution returns
Stream solvent is also concentrated to dryness, and the residue 10mL that adds water dissolves, and extracts 5 times with the shaking of water saturated n-butyl alcohol, each 20mL, and merging is just
Butyl alcohol extraction liquid, washs 3 times with ammonia solution, each 15mL, and n-butanol extracting liquid recycling design is to dry, and residue adds methanol and dissolves also
It is transferred in 10mL volumetric flask, adds methanol to scale, shake up, filter, take filtrate, obtain need testing solution;
(4) measure: precision measures above-mentioned need testing solution, each 10 μ L of reference substance solution respectively, inject high performance liquid chromatograph, enter
Row detection, testing result be the content of euscaphic acid Jacaric acid be 0.1823mg/g.
Although moreover, it will be appreciated that this specification is been described by according to embodiment, but the most each embodiment only wraps
Containing an independent technical scheme, this narrating mode of description is only that for clarity sake those skilled in the art should
Description can also be formed those skilled in the art through appropriately combined as an entirety, the technical scheme in each embodiment
May be appreciated other embodiments.
Claims (10)
1. the medicine treating polycystic ovarian syndrome, it is characterised in that this medicine is made up of the raw material of following weight portion
: Rosa bella Rehd et wils 1~2 weight portion, yellow calamite 1~2 weight portion.
2. medicine as claimed in claim 1, it is characterised in that this medicine is made up of the raw material of following weight portion: Mei Qiangwie
Really 1 weight portion, yellow calamite 2 weight portion.
3. medicine as claimed in claim 1, it is characterised in that this medicine is made up of the raw material of following weight portion: Mei Qiangwie
Really 2 weight portion, yellow calamite 1 weight portion.
4. such as claim 1 medicine, it is characterised in that this medicine is made up of the raw material of following weight portion: Rosa bella Rehd et wils 1 weight
Amount part, yellow calamite 1 weight portion.
5. the medicine as described in any one in Claims 1 to 4, it is characterised in that this medicine is prepared as tablet, pill, dissipates
Agent, hard capsule, soft capsule, granule, oral liquid.
6. medicine as claimed in claim 5, it is characterised in that this medicine is adopted and prepared with the following method: take Rosa bella Rehd et wils, Huang Lu
Wood, mixing, the water soaking 0.5 of addition 3~15 times amount~2 hours, decoct 0.5~2 hour, decoct 2~4 times, each 0.5~2
Hour, extracting solution merges, and filters, and filtrate concentrates, and dry, pulverize into fine powder, adds adjuvant, mixing, loads hard capsule, to obtain final product.
7. medicine as claimed in claim 6, it is characterised in that this medicine is adopted and prepared with the following method: take dry Mei Qiangwie
Really, yellow calamite, add 11 times amount water soaking 1 hour for the first time, decoct 1 hour, second time adds 4 times amount soak by water 1 hour, merging water
Decocting liquid, filters, and filtrate concentrates, and dry, pulverize into fine powder, sieves, and mixing loads hard capsule, to obtain final product.
8. a quality determining method for medicine, this medicine is made up of the raw material of following weight portion: Rosa bella Rehd et wils 1~2 weight
Amount part, yellow calamite 1~2 weight portion, it is characterised in that detection with the following method adopted by this medicine: use high performance liquid chromatography to enter
The assay of row euscaphic acid Jacaric acid:
(1) chromatographic condition: use HypersilDs chromatographic column;Flowing phase: ratio is the acetonitrile-water of 20~40:60~80;Detection
Wavelength: 190~210nm;Column temperature: 15~25 DEG C;Flow velocity: 0.5~1.5mL min-1;Sample size: 5~20 μ L;
(2) prepared by reference substance solution: it is appropriate that precision weighs the euscaphic acid Jacaric acid reference substance being dried to constant weight, adds methanol dissolving and makes comparison
Product solution;
(3) preparation of need testing solution: precision weighs medicine of the present invention, adds methanol, is heated to reflux, extracting solution reflux solvent is the denseest
Being reduced to do, residue is dissolved in water, and extracts with the shaking of water saturated n-butyl alcohol, merges n-butanol extracting liquid, washs with ammonia solution, just
Butyl alcohol extraction liquid recycling design is to dry, and residue adds methanol and dissolves, and shakes up, and filters, takes filtrate, obtain need testing solution;
(4) measure: precision measures above-mentioned need testing solution, reference substance solution each 5~20 μ L respectively, inject high performance liquid chromatography
Instrument, detects.
9. the quality determining method of as claimed in claim 8 medicine, this medicine is made up of the raw material of following weight portion: U.S. rose
Common vetch fruit 1~2 weight portions, yellow calamite 1~2 weight portion, it is characterised in that detection with the following method adopted by this medicine: use high-efficient liquid
Phase chromatography carries out the assay of euscaphic acid Jacaric acid:
(1) chromatographic condition: use HypersilDs chromatographic column;Flowing phase: ratio is the acetonitrile-water of 30:70;Detection wavelength:
200nm;Column temperature: 20 DEG C;Flow velocity: 1.0mL min-1;Sample size: 10 μ L;
(2) prepared by reference substance solution: precision weighs 80 DEG C and is dried to the euscaphic acid Jacaric acid reference substance of constant weight appropriate, adds methanol dissolving and makes
Every 1mL reference substance solution containing 0.2mg;
(3) preparation of need testing solution: precision weighs medicine 10g of the present invention, adds methanol 40mL, is heated to reflux 4h, and extracting solution returns
Stream solvent is also concentrated to dryness, and the residue 10mL that adds water dissolves, and extracts 5 times with the shaking of water saturated n-butyl alcohol, each 20mL, and merging is just
Butyl alcohol extraction liquid, washs 3 times with ammonia solution, each 15mL, and n-butanol extracting liquid recycling design is to dry, and residue adds methanol and dissolves also
It is transferred in 10mL volumetric flask, adds methanol to scale, shake up, filter, take filtrate, obtain need testing solution;
(4) measure: precision measures above-mentioned need testing solution, each 10 μ L of reference substance solution respectively, inject high performance liquid chromatograph, enter
Row detection.
10. the medicine as described in any one in Claims 1 to 4 is in the medicine or health product of preparation treatment ovarian cyst
Application.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610476727.6A CN105943658B (en) | 2016-06-27 | 2016-06-27 | A kind of medicine and its preparation method and purposes for treating polycystic ovarian syndrome |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610476727.6A CN105943658B (en) | 2016-06-27 | 2016-06-27 | A kind of medicine and its preparation method and purposes for treating polycystic ovarian syndrome |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105943658A true CN105943658A (en) | 2016-09-21 |
CN105943658B CN105943658B (en) | 2017-03-29 |
Family
ID=56904183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610476727.6A Active CN105943658B (en) | 2016-06-27 | 2016-06-27 | A kind of medicine and its preparation method and purposes for treating polycystic ovarian syndrome |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105943658B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1977948A (en) * | 2005-11-29 | 2007-06-13 | 绿谷(集团)有限公司 | Chinese medicine composition for treating high insulin polycystic ovary syndrome |
CN105125807A (en) * | 2015-10-22 | 2015-12-09 | 陈远征 | Traditional Chinese medicine combination for treating adolescent polycystic ovary syndromes |
-
2016
- 2016-06-27 CN CN201610476727.6A patent/CN105943658B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1977948A (en) * | 2005-11-29 | 2007-06-13 | 绿谷(集团)有限公司 | Chinese medicine composition for treating high insulin polycystic ovary syndrome |
CN105125807A (en) * | 2015-10-22 | 2015-12-09 | 陈远征 | Traditional Chinese medicine combination for treating adolescent polycystic ovary syndromes |
Non-Patent Citations (5)
Title |
---|
刘颖华;等: "名老中医治疗多囊卵巢综合征经验总结", 《中华中医药学刊》 * |
向兰;等: "美蔷薇果实化学成分的研究", 《中国中药杂志》 * |
潘萍;等: "RP-HPLC 法测定大叶紫珠中蔷薇酸的含量", 《药物分析杂志》 * |
王晓闻;等: "美蔷薇果实开发应用探讨", 《山西农业大学学报》 * |
鲁彩霞;等: "黄连素治疗多囊卵巢综合征 30 例", 《中医研究》 * |
Also Published As
Publication number | Publication date |
---|---|
CN105943658B (en) | 2017-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102258685B (en) | Compound traditional Chinese medicine for treating diminished ovarian reserve and application | |
CN105031559B (en) | It is a kind of to treat the Chinese medicine for causing infertility by Stein-Leventhal syndrome | |
CN101342353A (en) | Traditional Chinese medicine preparation for treating barrenness and preparation method thereof | |
CN103800670A (en) | Traditional Chinese medicinal preparation for treating kidney-yang deficiency and preparation method thereof | |
CN102988703A (en) | Traditional Chinese medicine preparation for treating kidney-yang deficiency and preparation method thereof | |
CN102764404A (en) | Traditional Chinese medicine formula for reinforcing kidneys and promoting pregnancy | |
CN1332710C (en) | Kidney replenishing medicinal composition and its preparation process and novel use | |
Jo et al. | Effects of traditional Korean medicine on anti-Müllerian hormone in patients with diminished ovarian reserve: a retrospective study | |
CN102302659B (en) | Chinese medicinal composition for kidney-yang deficiency and phlegm-retention type polycystic ovanian syndrome | |
CN109528980A (en) | A kind of Chinese medicine composition and its pharmacy application for treating Ovary reserve decline disease | |
CN101332282B (en) | Traditional Chinese medicine composition for treating gynecologic diseases from kidney deficiency and genitals coldness, and its preparation method | |
CN105943758B (en) | A kind of Chinese medicine composition that treating infertility and its application | |
CN102861159B (en) | Medicine composition for treating dysmenorrheal as well as preparation method and application thereof | |
CN102125671B (en) | Traditional Chinese medicinal composition for treating gynaecopathia caused by deficiency of the kidney and cold and preparation method thereof | |
CN105943658B (en) | A kind of medicine and its preparation method and purposes for treating polycystic ovarian syndrome | |
CN102048913B (en) | Traditional Chinese medicine preparation for treating climacteric syndrome and preparation method thereof | |
CN106237027B (en) | It is a kind of to treat pharmaceutical composition of gynecological disease and preparation method thereof | |
CN104189356B (en) | A kind of pharmaceutical composition for the treatment of or auxiliary treatment infertility and its production and use | |
CN103071018A (en) | Traditional Chinese medicine preparation for treating early habitual abortion | |
CN100360159C (en) | Kidney benefiting, Chong collateral reinforcing and menstruation regulating hemostat | |
CN101766743A (en) | Drug combination for treating permenstrual syndrome | |
CN117442659B (en) | Kidney-tonifying spleen-regulating liver-soothing composition and preparation method and application thereof | |
CN107213426A (en) | Treat Chinese patent drug of mammary gland disease and preparation method thereof | |
CN105311396A (en) | Traditional Chinese medicine preparation for treating hypomenorrhea caused by thin endometrium | |
CN105833209A (en) | Traditional Chinese medicine composition for treating endometriosis uterina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |